Can broadly neutralizing HIV-1 antibodies help achieve an ART-free remission?
DC Hsu, JW Mellors, S Vasan - Frontiers in Immunology, 2021 - frontiersin.org
Many broadly neutralizing antibodies (bnAbs) targeting the HIV-1 envelope glycoprotein are
being assessed in clinical trials as strategies for HIV-1 prevention, treatment, and …
being assessed in clinical trials as strategies for HIV-1 prevention, treatment, and …
Single-cell transcriptomics identifies prothymosin α restriction of HIV-1 in vivo
A Geretz, PK Ehrenberg, RJ Clifford… - Science Translational …, 2023 - science.org
Host restriction factors play key roles in innate antiviral defense, but it remains poorly
understood which of them restricts HIV-1 in vivo. Here, we used single-cell transcriptomic …
understood which of them restricts HIV-1 in vivo. Here, we used single-cell transcriptomic …
Estimation of the incubation period of COVID-19 using viral load data
The incubation period, or the time from infection to symptom onset, of COVID-19 has usually
been estimated by using data collected through interviews with cases and their contacts …
been estimated by using data collected through interviews with cases and their contacts …
TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption
DC Hsu, A Schuetz, R Imerbsin, D Silsorn… - PLoS …, 2021 - journals.plos.org
Toll-like receptor 7 (TLR7) agonist and PGT121 (broadly neutralizing antibody, bnAb)
administration previously delayed viral rebound and induced SHIV remission. We evaluated …
administration previously delayed viral rebound and induced SHIV remission. We evaluated …
HIV-1 entry and prospects for protecting against infection
Human Immunodeficiency Virus type-1 (HIV-1) establishes a latent viral reservoir soon after
infection, which poses a major challenge for drug treatment and curative strategies. Many …
infection, which poses a major challenge for drug treatment and curative strategies. Many …
New SHIVs and improved design strategy for modeling HIV-1 transmission, immunopathogenesis, prevention, and cure
H Li, S Wang, FH Lee, RS Roark, AI Murphy… - Journal of …, 2021 - Am Soc Microbiol
Previously, we showed that substitution of HIV-1 envelope (Env) residue 375-Ser by bulky
aromatic residues enhances binding to rhesus CD4 and enables primary HIV-1 Envs to …
aromatic residues enhances binding to rhesus CD4 and enables primary HIV-1 Envs to …
[HTML][HTML] B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies
Determining which immunological mechanisms contribute to the development of broad
neutralizing antibodies (bNAbs) during HIV-1 infection is a major goal to inform vaccine …
neutralizing antibodies (bNAbs) during HIV-1 infection is a major goal to inform vaccine …
Timing HIV infection with a simple and accurate population viral dynamics model
Clinical trials for HIV prevention can require knowledge of infection times to subsequently
determine protective drug levels. Yet, infection timing is difficult when study visits are sparse …
determine protective drug levels. Yet, infection timing is difficult when study visits are sparse …
IFNα induces CCR5 in CD4+ T cells of HIV patients causing pathogenic elevation
H Le Buanec, V Schiavon, M Merandet… - Communications …, 2024 - nature.com
Background Among people living with HIV, elite controllers (ECs) maintain an undetectable
viral load, even without receiving anti-HIV therapy. In non-EC patients, this therapy leads to …
viral load, even without receiving anti-HIV therapy. In non-EC patients, this therapy leads to …
Estimation of timing of infection from longitudinal SARS-CoV-2 viral load data: mathematical modelling study
Background Multiple waves of the COVID-19 epidemic have hit most countries by the end of
2021. Most of those waves are caused by emergence and importation of new variants. To …
2021. Most of those waves are caused by emergence and importation of new variants. To …